Novo Nordisk (CPSE:NOVO B) has quietly slipped over the past year, even as its diabetes and obesity franchise keeps growing. That disconnect between share performance and earnings momentum is where ...

If you are wondering whether Novo Nordisk is a rare bargain or a value trap at today's price, you are not alone. This breakdown will help you see what the market might be missing. The stock has ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Is RENK’s stock better than Hensoldt’s? That is what analysts are saying. According to them, the transmission specialist is ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for diabetes) and Wegovy (for obesity). Despite being NVO’s key ...

US stock futures trimmed losses as dip buyers stepped in after concerns over Oracle Corp.’s plans for vast capital outlays on ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...